GB1422263A - 4-phenyl-piperidine compounds - Google Patents

4-phenyl-piperidine compounds

Info

Publication number
GB1422263A
GB1422263A GB449673A GB449673A GB1422263A GB 1422263 A GB1422263 A GB 1422263A GB 449673 A GB449673 A GB 449673A GB 449673 A GB449673 A GB 449673A GB 1422263 A GB1422263 A GB 1422263A
Authority
GB
United Kingdom
Prior art keywords
alkyl
phenyl
jan
alkoxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB449673A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrosan ApS
Original Assignee
Ferrosan ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB1422263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan ApS filed Critical Ferrosan ApS
Priority to GB449673A priority Critical patent/GB1422263A/en
Priority to US435006A priority patent/US3912743A/en
Priority to CA191,106A priority patent/CA1038390A/en
Priority to IE166/74A priority patent/IE38801B1/xx
Priority to LU69264A priority patent/LU69264A1/xx
Priority to BE140304A priority patent/BE810310A/xx
Priority to CH121774A priority patent/CH592059A5/xx
Priority to ES422734A priority patent/ES422734A1/es
Priority to JP49011523A priority patent/JPS5946216B2/ja
Priority to FI243/74A priority patent/FI57932C/fi
Priority to FR7402823A priority patent/FR2215233B1/fr
Priority to AT69674*#A priority patent/AT333759B/de
Priority to SE7401101A priority patent/SE401827B/xx
Priority to PH15445A priority patent/PH10383A/en
Priority to DK045274A priority patent/DK149843C/da
Priority to DE2404113A priority patent/DE2404113C2/de
Priority to NO740272A priority patent/NO144568C/no
Priority to NLAANVRAGE7401189,A priority patent/NL179187C/xx
Priority to IT19998/74A priority patent/IT1054157B/it
Priority to US05/598,146 priority patent/US4007196A/en
Publication of GB1422263A publication Critical patent/GB1422263A/en
Priority to HK130/81A priority patent/HK13081A/xx
Priority to JP58025524A priority patent/JPS5948826B2/ja
Priority to ES556013A priority patent/ES556013A0/es
Priority to NL930003C priority patent/NL930003I2/nl
Priority to LU88398C priority patent/LU88398I2/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB449673A 1973-01-30 1973-01-30 4-phenyl-piperidine compounds Expired GB1422263A (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds
US435006A US3912743A (en) 1973-01-30 1974-01-21 4-Phenylpiperidine compounds
CA191,106A CA1038390A (en) 1973-01-30 1974-01-28 Ethers of 2-hydroxymethyl-4-phenylpiperidine compounds
NLAANVRAGE7401189,A NL179187C (nl) 1973-01-30 1974-01-29 Werkwijze voor het bereiden van een geneesmiddel; een aldus gevormd geneesmiddel; en een werkwijze voor het bereiden van geneeskrachtige verbindingen.
SE7401101A SE401827B (sv) 1973-01-30 1974-01-29 Sett att framstella 1-och3-substituerade 4-fenylpiperidiner
DK045274A DK149843C (da) 1973-01-30 1974-01-29 Analogifremgangsmaade til fremstilling af 3-substituerede 4-fenylpiperidiner eller salte deraf med farmaceutisk acceptable syrer
BE140304A BE810310A (fr) 1973-01-30 1974-01-29 4-phenylpiperidines et leur preparation
CH121774A CH592059A5 (enExample) 1973-01-30 1974-01-29
ES422734A ES422734A1 (es) 1973-01-30 1974-01-29 Metodo para la produccion de 1-alcohil-4-fenilpiperidinas sustituidas en la posicion 3.
JP49011523A JPS5946216B2 (ja) 1973-01-30 1974-01-29 ４−フエニルピペリジン化合物の製法
FI243/74A FI57932C (fi) 1973-01-30 1974-01-29 Foerfarande foer framstaellning av 3-substituerade 4-fenylpiperidiner med antidepressiv och anti-parkinson verkan
FR7402823A FR2215233B1 (enExample) 1973-01-30 1974-01-29
AT69674*#A AT333759B (de) 1973-01-30 1974-01-29 Verfahren zur herstellung von neuen 3-subst.-4-phenylpiperidinen und von deren salzen
IE166/74A IE38801B1 (en) 1973-01-30 1974-01-29 4-phenylpiperidine compounds
PH15445A PH10383A (en) 1973-01-30 1974-01-29 4-phenylpiperidine compounds
LU69264A LU69264A1 (enExample) 1973-01-30 1974-01-29
DE2404113A DE2404113C2 (de) 1973-01-30 1974-01-29 3-Substituierte 4-Phenylpiperidine und ihre Salze mit pharmazeutisch annehmbaren Säuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
NO740272A NO144568C (no) 1973-01-30 1974-01-29 Analogifremgangsmaate til fremstilling av 3-substituerte 4-fenylpiperidiner
IT19998/74A IT1054157B (it) 1973-01-30 1974-01-30 Metodo per la preparazioni di composti della 4.fenilpiperidina
US05/598,146 US4007196A (en) 1973-01-30 1975-07-23 4-Phenylpiperidine compounds
HK130/81A HK13081A (en) 1973-01-30 1981-04-02 4-phenylpiperidine compounds
JP58025524A JPS5948826B2 (ja) 1973-01-30 1983-02-19 ４−フエニルピペリジン化合物の製法
ES556013A ES556013A0 (es) 1973-01-30 1986-06-13 Procedimiento para la obtencion de trans-4-(p-fluorofenil)-3-((3,4-(metilendioxi)fenoxi)metil)piperidina
NL930003C NL930003I2 (nl) 1973-01-30 1993-01-01 Werkwijze voor het bereiden van een geneesmiddel; een aldus gevormd geneesmiddel; en een werkwijze voor het bereiden van geneeskrachtige verbindingen.
LU88398C LU88398I2 (fr) 1973-01-30 1993-08-31 Seroxat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (1)

Publication Number Publication Date
GB1422263A true GB1422263A (en) 1976-01-21

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
GB449673A Expired GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Country Status (20)

Country Link
US (2) US3912743A (enExample)
JP (2) JPS5946216B2 (enExample)
AT (1) AT333759B (enExample)
BE (1) BE810310A (enExample)
CA (1) CA1038390A (enExample)
CH (1) CH592059A5 (enExample)
DE (1) DE2404113C2 (enExample)
DK (1) DK149843C (enExample)
ES (2) ES422734A1 (enExample)
FI (1) FI57932C (enExample)
FR (1) FR2215233B1 (enExample)
GB (1) GB1422263A (enExample)
HK (1) HK13081A (enExample)
IE (1) IE38801B1 (enExample)
IT (1) IT1054157B (enExample)
LU (2) LU69264A1 (enExample)
NL (2) NL179187C (enExample)
NO (1) NO144568C (enExample)
PH (1) PH10383A (enExample)
SE (1) SE401827B (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123832A1 (en) * 1983-03-07 1984-11-07 A/S Ferrosan Process for the optical resolution of a mixture of the enantiomers of trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidine
EP0223334A1 (en) * 1985-08-10 1987-05-27 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
EP0339579A3 (en) * 1988-04-28 1991-12-18 Novo Nordisk A/S Piperidine compositions and their preparation and use
WO1992001672A1 (en) * 1990-07-18 1992-02-06 Novo Nordisk A/S Piperidine compounds, their preparation and use
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
US5874447A (en) * 1997-06-10 1999-02-23 Synthon B. V. 4-Phenylpiperidine compounds for treating depression
US6063927A (en) * 1998-07-02 2000-05-16 Smithkline Beecham Plc Paroxetine derivatives
EP2303859A4 (en) * 2008-06-20 2012-08-22 Metabolex Inc ARYL GPR119 AGONISTS AND USES THEREOF
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8846675B2 (en) 2007-07-19 2014-09-30 Cymabay Therapeutics, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (en) * 1993-08-19 1995-02-22 Novo Nordisk A/S Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
CA2220963A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (en) 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
ES2329739T3 (es) * 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
NZ501285A (en) * 1997-05-29 2001-10-26 Smithkline Beecham Corp Process for preparing 4-(4'-fluorophenyl)-3-(3', 4'-methylenedioxy-phenyl)-piperidine
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
CA2212451C (en) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Stereoselective and useful preparation of 3-substituted 4-aryl piperidine compounds
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
CA2323896A1 (en) * 1998-03-16 1999-09-23 Andrew Simon Craig Crystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SK15032000A3 (sk) * 1998-04-09 2001-04-09 Smithkline Beecham Plc Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
DE69910691T2 (de) 1998-06-29 2004-07-08 Sumika Fine Chemical Co. Ltd. L-Tartrate von Trans-(-)-4-(4-Fluorphenyl)-3-Hydroxymethyl-Piperidin Verbindungen und Verfahren zu ihrer Herstellung
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
PT1100796E (pt) * 1998-08-07 2003-09-30 Smithkline Beecham Plc Processo para a preparacao de um cloridrato de paroxetina na forma anidra nao cristalina
US6440996B1 (en) 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
WO2000032594A1 (en) * 1998-11-30 2000-06-08 Smithkline Beecham Plc Mixed paroxetine propan-2-ol solvates
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
EP1140832A4 (en) * 1998-12-22 2004-11-03 Pentech Pharmaceuticals Inc PROCESS FOR THE PREPARATION OF INTERMEDIATES AND DERIVATIVES OF ARYLPIPERIDINE CARBINOL
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
US6984632B1 (en) * 1999-07-01 2006-01-10 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
WO2001029002A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of 4-(fluorophenyl)piperidine esters
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
CZ20023694A3 (cs) 2000-05-12 2003-05-14 Synthon B. V. Tosylátové soli 4-(p-fluorfenyl)-piperidin-3-methanolů
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
WO2002006275A1 (en) * 2000-07-17 2002-01-24 Smithkline Beecham P.L.C. Novel processes for the preparation of 4-phenylpiperidine derivatives
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
AU2001211337A1 (en) * 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
AU2001210390A1 (en) * 2000-10-20 2002-04-29 Smithkline Beecham Plc Process of the preparation of 3-substituted-4-aryl piperidine compounds
JP2004520333A (ja) * 2001-01-04 2004-07-08 フエルレル インターナショナル，ソシエダッド アノニマ （±）−トランス−４−ｐ−フルオロフェニル−３−ヒドロキシメチル−１−メチルピペリジンの製造方法。
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040073038A1 (en) * 2001-02-24 2004-04-15 Callewaert George Leo Process of preparing paroxetine and intermediates for use therein
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
JP2006512278A (ja) * 2001-06-13 2006-04-13 テバ ファーマシューティカル インダストリーズ リミティド アルコキシ不純物を実質的に含有しないパロキセチンの製造方法
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
NZ532432A (en) 2001-10-22 2005-02-25 Synthon Bv N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
AU2002359857B8 (en) * 2001-12-28 2009-01-08 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
DE60331762D1 (de) * 2002-11-01 2010-04-29 Neurosearch As Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer
WO2004043921A1 (en) * 2002-11-11 2004-05-27 Natco Pharma Limited Novel process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines.
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
SG146683A1 (en) * 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
WO2007008758A2 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
SI2358676T1 (sl) * 2008-11-14 2013-01-31 Theravance, Inc. Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
EP2810942B1 (en) 2012-01-31 2016-03-30 Eisai R&D Management Co., Ltd. Paroxetine derivative
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
US20250042855A1 (en) * 2021-12-02 2025-02-06 The Johns Hopkins University Peripherally and luminally-restricted inhibitors of the serotonin transporter as treatments for disorders of gastrointestinal motility and gut-brain axis
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123832A1 (en) * 1983-03-07 1984-11-07 A/S Ferrosan Process for the optical resolution of a mixture of the enantiomers of trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidine
US4571424A (en) * 1983-03-07 1986-02-18 A/S Ferrosan Optical resolution of racemic femoxetine
EP0223334A1 (en) * 1985-08-10 1987-05-27 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
AU582456B2 (en) * 1985-08-10 1989-03-23 Beecham Group Plc Preparation of 4-aryl-3-hydroxymethyl piperidines
US4902801A (en) * 1985-08-10 1990-02-20 Beecham Group Plc. Process for preparing aryl-piperidine carbinols and novel intermediates used in the process
EP0339579A3 (en) * 1988-04-28 1991-12-18 Novo Nordisk A/S Piperidine compositions and their preparation and use
WO1992001672A1 (en) * 1990-07-18 1992-02-06 Novo Nordisk A/S Piperidine compounds, their preparation and use
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
WO1994003428A1 (en) * 1992-08-06 1994-02-17 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
US7598271B1 (en) 1997-06-10 2009-10-06 Noven Therapeutics, Llc Crystalline paroxetine methane sulfonate
US6900327B2 (en) 1997-06-10 2005-05-31 Synthon Bct Technologies, Llc 4-phenylpiperidine compounds
US5874447A (en) * 1997-06-10 1999-02-23 Synthon B. V. 4-Phenylpiperidine compounds for treating depression
US6063927A (en) * 1998-07-02 2000-05-16 Smithkline Beecham Plc Paroxetine derivatives
US8975258B2 (en) 2006-12-28 2015-03-10 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9925189B2 (en) 2006-12-28 2018-03-27 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9737537B2 (en) 2006-12-28 2017-08-22 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8846675B2 (en) 2007-07-19 2014-09-30 Cymabay Therapeutics, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2303859A4 (en) * 2008-06-20 2012-08-22 Metabolex Inc ARYL GPR119 AGONISTS AND USES THEREOF
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8815886B2 (en) 2009-10-01 2014-08-26 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10098843B2 (en) 2010-06-23 2018-10-16 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Also Published As

Publication number Publication date
JPS58174363A (ja) 1983-10-13
FI57932C (fi) 1980-11-10
LU88398I2 (fr) 1994-05-04
ATA69674A (de) 1976-04-15
JPS5948826B2 (ja) 1984-11-29
JPS49101385A (enExample) 1974-09-25
US3912743A (en) 1975-10-14
NL179187B (nl) 1986-03-03
ES8707224A3 (es) 1987-07-16
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
HK13081A (en) 1981-04-10
BE810310A (fr) 1974-05-16
LU69264A1 (enExample) 1974-04-10
JPS5946216B2 (ja) 1984-11-10
FI57932B (fi) 1980-07-31
IE38801L (en) 1974-07-30
US4007196A (en) 1977-02-08
FR2215233A1 (enExample) 1974-08-23
NO144568B (no) 1981-06-15
CH592059A5 (enExample) 1977-10-14
DK149843C (da) 1987-06-15
IT1054157B (it) 1981-11-10
ES422734A1 (es) 1976-04-01
IE38801B1 (en) 1978-06-07
NL930003I2 (nl) 1994-03-01
CA1038390A (en) 1978-09-12
SE401827B (sv) 1978-05-29
DK149843B (da) 1986-10-13
NL7401189A (enExample) 1974-08-01
DE2404113C2 (de) 1985-07-11
DE2404113A1 (de) 1974-08-08
ES556013A0 (es) 1987-07-16
AT333759B (de) 1976-12-10
PH10383A (en) 1977-03-02
FR2215233B1 (enExample) 1977-01-28
NO144568C (no) 1981-09-23

Similar Documents

Publication Publication Date Title
IE38801B1 (en) 4-phenylpiperidine compounds
AU537414B2 (en) Pyroglutamic acid derivatives
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
ES480542A1 (es) Metodo para producir derivados de imidazol.
ES8407025A1 (es) Un procedimiento para preparar derivados de nicotinamida.
ES8609204A1 (es) Procedimiento de preparar derivados aminicos
ES8705853A1 (es) Un procedimiento para la produccion de derivados de benzoilurea
ES464045A1 (es) Un procedimiento para la produccion de una gamma-pirona.
IE832323L (en) Dioxocyclobutenes
ES8304920A1 (es) Un procedimiento para preparar derivados de n-acil-n-hidroxi-a minoacidos.
AU525735B2 (en) Diuretic composition
GB1529551A (en) Benzofuran derivatives
HUT39158A (en) Process for preparing carbacyclines and pharmaceutical compositions containing such compounds
KR890008100A (ko) 에테르 화합물, 그의 제조방법, 활성성분으로서 그를 함유하는 조성물 및 그의 용도
ES2024332A6 (es) Procedimiento para la obtencion de nuevas sulfonamidas.
ES476273A1 (es) Un procedimiento para preparar nuevos analogos de cefalospo-rina
ES8407318A1 (es) Procedimiento de preparacion de derivados de piperacina.
EP0230474A4 (en) BIS-DIOXOPIPERAZINE COMBATS AND MEDICINAL PRODUCTS THEREOF.
JPS5359664A (en) Novel imidazole derivatives
AU579416B2 (en) 3-Amino-2,3-dihydro-1-benzoxepine-compounds and methods for their preparation and pharmaceutical preparations containing these compounds
MY101628A (en) Sulfonamide compounds and salts thereof, herbicidal compositions containing them, and process for producing them.
GB1436214A (en) Amido containing phosphorothiolate pesticide
ES8400420A1 (es) "procedimiento para la fabricacion de derivados n- susbtituidos de la tetrahidroisftalimida".
ES8602744A1 (es) Procedimiento de obtencion de nuevos derivados -(alquilamino-propionil)-tiofeno sustituidos en el anillo tiofenico
ES440905A1 (es) Un procedimiento para la preparacion de una composicion her-bicida.

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
429A Application made for amendment of specification (sect. 29/1949)
429H Application (made) for amendment of specification now open to opposition (sect. 29/1949)
429D Case decided by the comptroller ** specification amended (sect. 29/1949)
SP Amendment (slips) printed
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
704A Declaration that licence is not available as of right for an excepted use (par. 4a/1977)
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
CTFF Supplementary protection certificate filed

Free format text: SPC/GB93/010, 930128

CTFA Application for supplementary protection certificate granted

Free format text: SPC/GB93/010, 930928, EXPIRES:19990122

PE20 Patent expired after termination of 20 years

Effective date: 19940122

CTFG Supplementary protection certificate granted

Free format text: SPC/GB93/010, 940123, EXPIRES:19990122

SPCE Supplementary protection certificate expired

Free format text: SPC/GB93/010, 19990122